Introduction: Male Sickle cell disease (ScD) patients often have moderate to severe hypogonadism resulting in abnormal seminal fluid parameters due to testicular dysfunction. Hydroxyurea (HU), the only drug found to be effective in preventing morbidity and mortality in sickle cell disease patients has been found to further aggravate the testicular dysfunction.
Introduction

S ickle cell anemia is one of t h e m o s t c o m m o n h u m a n a u t o s o m a l r e c e s s i ve d i s o r d e r
caused by a mutational substitution of thymine for adenine in the sixth codon (GAG to GTG) of the globin gene on chromosome 11p. 1 Sickle cell anemia patients often have moderate to severe hypogonadism of unknown origin, a l t h o u g h s e ve r a l m e c h a n i s m s have been suggested like: primary
Editorial Viewpoint
• SCD patients have hypogonadism due to testicular dysfunction which may be further aggravated by hydroxyurea.
• This study confirms above even with low doses of hydroxyurea.
• There is a need to monitor seminal fluid parameters regularly in young adults w i t h S C D r e c e i v i n g hydroxyurea.
hypogonadism, 2-5 hypogonadism induced by repeated testicular infarction, 6 zinc deficiency, 7, 8 and puberty delay due to span height retardation.
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Hydroxyurea remains the only a p p r o v e d d i s e a s e m o d i f y i n g therapy for sickle cell anemia. 1 Hydroxyurea increases the fetal hemoglobin which has higher o x y g e n c a r r y i n g c a p a c i t y a n d does not undergo sickling under low oxygen tension. Low dose h y d r o x y u r e a t h e r a p y ( 1 0 m g / kg/day) is found to be effective i n i m p r o v i n g c l i n i c a l a n d hematological parameters in sickle cell anemia with improved quality of life. Hydroxyurea being an antimitotic agent has been reported to impair human spermatogenesis. Hydroxyurea is also associated with testicular atrophy, 12-14 a reversible decrease in sperm count [12] [13] [14] and abnormal sperm morphology [13] [14] and motility. 12 So, hydroxyurea t r e a t m e n t c a n a g g r a va t e t h e testicular dysfunction in sickle cell disease patients.
Sickle cell anemia is a major public health problem in the state of Odisha, India. The sickle gene frequency is 10-30% in general p o p u l a t i o n i n O d i s h a ( Pa t e l DK). 15 The use of hydroxyurea is increasing in sickle cell anemia patients due to its beneficial effect in reducing painful crises and blood transfusion requirement but there are limitations to hydroxyurea because of its toxicities. Sickle cell disease itself causes abnormalities i n s e m i n a l f l u i d p a r a m e t e r s , which also may be aggravated by hydroxyurea therapy. On the basis of the above observations, we conducted this study to evaluate seminal fluid parameters and fertility of men suffering from sickle cell disease and to analyze the potential impact of hydroxyurea. 
Material and Methods
Screening, Diagnosis and Clinical Evaluation
Screening of Sickle Cell Anemia was initially done by sickling slide test. Those found positive were subjected to agarose gel Hb electrophoresis in an alkaline medium (pH 8.6). Quantification of various hemoglobin including HbF, HbS was done by High Performance Liquid Chromatography (HPLC) using VARIANT TM Hemoglobin t a s t i n g s y s t e m ( B i o -R a d L a b , H e r c u l e s , C A , U S A) o n t h e p r i n c i p l e o f c a t i o n e x c h a n g e HPLC according to manufacturer's guidelines. Confirmation of Sickle Cell Disease (codon 6=GAG to G T G m u t a t i o n ) wa s d o n e b y amplification refractory mutation system-Polymerase Chain Reaction (ARMS-PCR) using established protocols. 16 Total 100 patients were divided into 2 groups. Group I included 50 patients without hydroxyurea therapy and Group II included 50 patients who needed hydroxyurea therapy and had normal sperm parameters prior to hydroxyurea therapy. Group II patients were g i ve n l o w d o s e h y d r o x y u r e a t h e r a p y 1 0 m g / k g / d a y . S i c k l e cell anemia with 1 or more of the f o l l o w i n g c o m p l i c a t i o n s we r e included in Group II and were g i ve n l o w d o s e h y d r o x y u r e a therapy:-(a) painful crises ≥3 episodes in previous 1 year.; (b) ≥2 blood transfusions in last 1 year. Painful crisis was defined as an acute painful event that required oral/ inject ab le an alg esics and that lasted for at least 4 hrs when no other cause could explain the symptom.
A detailed history was taken in all cases with reference to age, marital status, fertility in form of number of issues, family history, history of painful crisis, blood transfusion. Married male sickle cell disease patients with regular sexual activity in form of regular unprotected sexual intercourse for 12 months or more were asked whether he had caused a pregnancy or not. Routine hematological evaluation like complete blood count, liver function tests, serum creatinine were done in all patients a n d r e p e a t e d e ve r y 3 m o n t h s following hydroxyurea therapy.
Group I patients were evaluated for seminal fluid analysis and those who had azoospermia were subjected for FNAC of testis. In Group II, seminal fluid analysis and routine hematological evaluation were done prior to hydroxyurea therapy and during hydroxyurea t h e r a p y e v e r y 3 m o n t h s . Hydroxyurea was temporarily stopped in those who developed o l i g o o r a z o o s p e r m i a d u r i n g hydroxyurea treatment and again tested for seminal quality after 3 months. Those who developed azoospermia were subjected to FNAC of testis. Hydroxyurea was restarted after normalization of sperm parameters.
Exclusion Criteria
Patients with following criteria were excluded from the study:-(a) patients with other sickle cell syndrome such as HbS/ß-thal, HbS/ HbE, HbS/HbC, HbS/HbD Punjab and others; (b) male patients <18yr and >45 yr; (c) patients who refused to give consent d) patients who had taken hydroxyurea for less than 80% of days.
Evaluation of Seminal Fluid Parameters
S e m i n a l f l u i d s a m p l e wa s collected in a sterile container by masturbation after minimum 3 days of sexual abstinence and analyzed after liquefaction according to WHO criteria. 17 The parameters assessed included volume of ejaculate, sperm concentration, motility, sperm morphology and viability. The normal semen volume is 2-6 ml, normal sperm concentration ≥ 15 million/ml, normal motility ≥40% motile [progressive (PR)+ nonprogressive(NP)] or ≥ 32% with progressive motility (PR), normal morphology in ≥4% of sperms and normal viability is ≥58% viable sperm (WHO 2010).
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Evaluation of Fertility
Evaluated by taking history of patient's marital status and whether the patient had caused at least one pregnancy.
FNAC (fine needle aspiration cytology of testis)
FNAC was done in patients who showed azoospermia. FNAC of testis was done with 22G needle by aseptic method after giving local xylocaine injection into spermatic c o r d b i l a t e r a l l y . S m e a r s we r e stained with hematoxylin and eosin (HandE) stain and examined under microscope (1250 magnification) for spermatogenic cells and sertoli cells.
Results
The mean age of sickle cell disease patients in Group I (nonhydroxyurea) was 26.02 ± 6.86 yrs and in Group II (with hydroxyurea) mean age was 25.86 ± 6.5 yrs. In our study clinical indication o f h y d r o x y u r e a t h e r a p y wa s painful crisis alone in 62% cases, repeated BT alone in 8% of cases and combined painful crisis and repeated BT in 30% of cases.
Evalution of fertility:
In our study, out of 50 non-hydroxyurea ( G r o u p I ) p a t i e n t s , 7 2 % we r e unmarried and 28% were married. 13 out 14 married men (93%) had caused at least one pregnancy. In 50 patients with hydroxyurea therapy (Group II), 86% patients were unmarried and 14% were married.6 out of 7 married men (85%) had caused at least one pregnancy.
S e m i n a l f l u i d p a r a m e t e r s in sickle cell disease patients without hydroxyurea therapy (Group I):
In 50 patients without hydroxyurea therapy, the mean sperm concentration was 48.60 ± 27.73 million/ml with oligospermia s e e n i n 9 p a t i e n t s ( 1 8 % ) a n d azoospermia in 2 patients (4%). The mean normal morphology was 77.3± 20.66% (Table 1) .
I m p a c t o f H y d r o x y u r e a o n Sperm Parameters in Group II :
Seminal fluid parameters prior to hydroxyurea therapy: The mean sperm concentration was 54.28 ± 16.2 million/ml and mean normal morphology was 85.3 ± 10.27% (Table 2) . S e m i n a l f l u i d p a r a m e t e r s during hydroxyurea therapy: The mean sperm concentration during hydroxyurea therapy was 39.26 ± 29.32 million/ml with normal morphology 73.3 ± 30.96% with oligospermia seen in 10 patients (20%) and azoospermia in 5 patients ( 1 0 % ) . C o m p a r i s o n o f s p e r m parameters before and during h y d r o x y u r e a t h e r a p y s h o we d significant reduction in sperm concentration (p value <0.0001) with reduction in both normal morphology and motility (Table 2) . m i n a l f l u i d p a r a m e t e r Table 2) .
S e
FNAC of testis:
FNAC of testis was done in 2 non-hydroxyurea patients with azoospermia and in 4 hydroxyurea receiving patients with azoospermia. In non-hydroxyurea (Group I), one patient showed absent spermatogenesis with other being normal. In hydroxyurea receiving group (Group II), three out of four patients showed absent spermatogenesis (Table 3) .
Discussion
B e c a u s e o f t h e l o n g e r l i f e e x p e c t a n c y o f s i c k l e c e l l disease patients due to advent o f h y d r o x y u r e a t h e r a p y , t h e e v a l u a t i o n o f p o s s i b l e s i d e effects of hydroxyurea on male fertility has therefore become a question of public health. Any deleterious impact of hydroxyurea on spermatogenesis and sperm parameters would represent a major concern necessitating advice on sperm cryopreservation as a preventive measure in order to preserve future male fertility. I n o u r s t u d y , we a n a l y z e d the seminal fluid parameters of 50 sickle cell disease patients w i t h o u t h y d r o x y u r e a t h e r a p y and 50 sickle cell disease patients with hydroxyurea therapy. In the sickle cell disease patients without hydroxyurea therapy, the mean sperm concentration Overall we detected 22% of oligoazoospermia in patients without h y d r o x y u r e a t h e r a p y . I n t h e study by Berthaut I. et al, 18 40% of individual values of concentration of spermatozoa was below normal and at least one sperm parameter was abnormal in 91% of patients before hydroxyurea treatment.
A decrease in semen volume in patients with sickle cell disease was previously described, 19 suggesting a s s o c i a t e d a b n o r m a l i t i e s l i k e disease of seminal vesicle, prostate. In our study, the volume of ejaculate was in normal range, in agreement with Osegbe et al 5 study, which did not find any significant difference in ejaculate volume between sickle cell disease patients and fertile male controls.
I n t h e p r e s e n t s e r i e s o f 5 0 patients who received low dose hydroxyurea therapy, there is significant reduction in mean sperm concentration when comparing semen before and during treatment (54.28 ± 16.2 v/s 39.26 ± 29.32 million/ml). During hydroxyurea t r e a t m e n t , 2 0 % o f p a t i e n t s developed oligospermia and 10% developed azoospermia. In the study by Berthaut I.et al, 18 where high dose hydroxyurea (20-30 mg/ kg/day) was used, showed affection of all sperm parameters in semen samples.
After stopping hydroxyurea t r e a t m e n t f o r 3 m o n t h s i n patients who developed oligo or azoospermia, 73% of patients reverted back to normal, indicating r e v e r s i b i l i t y o f h y d r o x y u r e a induced gonadal dysfunction in most cases.
In our study, FNAC of testis o f t w o a z o o s p e r m i c p a t i e n t s w i t h o u t h y d r o x y u r e a t h e r a p y showed absent spermatogenesis in one patient. FNAC of testis i n 4 a z o o s p e r m i c p a t i e n t s o n h y d r o x y u r e a t h e r a p y s h o we d a b s e n t s p e r m a t o g e n e s i s i n 3 patients. Jones et al 20 had found that, testes from hydroxyurea treated rats showed significant atrophic d e g e n e r a t i o n i n s e m i n i f e r o u s tubules compared to control.
Conclusion
The study has several limitations including a small sample size, lack of testing for gonadal hormones like FSH, LH and testosterone for confirming central or peripheral cause of hypogonadism and lack of testicular biopsy. Despite these limitations, the study indicates that alteration of sperm parameters is seen in a significant number of sickle cell disease patients. A l s o , a l t e r a t i o n s o f s p e r m parameters are exacerbated by hydroxyurea treatment even with low dose. Therefore, treatment with hydroxyurea in adolescent and adult male sickle cell disease patients should be preceded by routine assessment seminal fluid p a r a m e t e r s a n d f o l l o w e d u p regularly every 3 months for any change in sperm parameters for evidence of hydroxyurea toxicity. Hydroxyurea treatment should be stopped temporarily in patients who develop alteration of sperm parameters and again restarted a f t e r n o r m a l i z a t i o n o f s p e r m parameters.
